First study of PK/PD target attainment of echinocandins in critically ill patients.
Considerable PTA variability was observed for anidulafungin and micafungin in different patient populations.
For Candida albicans and C. glabrata, caspofungin is a reasonable choice for general and ICU patients.
For C. parapsilosis, an increased dose up to 100 mg once daily of caspofungin is needed.
For anidulafungin and micafungin, administering higher doses is needed in clinical applications.